AI+医疗行业深度：AI+医药：势不可挡，未来已至

Investment Rating - The industry investment rating is "Strong Outperform" and is maintained [1] Core Insights - The global market for "AI + Healthcare" solutions is expected to exceed $100 billion, entering a phase of accelerated commercialization. The market size is projected to grow from$13.7 billion in 2022 to $155.3 billion by 2030, with a CAGR of 35.5$43.3 billion in 2018 to $139.5 billion in 2022, with a CAGR of 34.0$13.7 billion in 2022 to $155.3 billion by 2030, with a CAGR of 35.5% [13][19] - The AI + Healthcare sector is anticipated to experience explosive growth in sub-sectors such as AI drug development, genetic sequencing, and surgical robots [13][19] Policy Support - The Chinese government has introduced several policies to promote the application of AI in healthcare, emphasizing the integration of AI technologies in drug development and healthcare services [14][15] Competitive Landscape - AI pharmaceutical companies are characterized by strong AI technology platforms and partnerships with large pharmaceutical firms, leading to rapid revenue growth. The companies are transitioning from AI-SaaS to AI-CRO models, with some evolving into AI-Biotech firms [5][26] - The report identifies key players in various segments, including AI + Drug Development (e.g., Crystal Holding, Hongbo Pharmaceutical), AI + Imaging (e.g., United Imaging, MicroPort), and AI + Diagnostic Assistance (e.g., BGI, RunDa Medical) [5][21] Investment Recommendations - The report suggests a prudent allocation strategy, focusing on sectors with clear commercialization models and significant technological replacement potential. Beneficiary stocks include Crystal Holding, Hongbo Pharmaceutical, BGI, and MicroPort [5][19] - For more speculative investments, areas such as AI + Wearables, AI + Brain-Computer Interfaces, and AI + Gene Editing are highlighted, with potential beneficiaries including Loxin Medical and Sanbo Brain Science [5][19]